Preliminary results with non-centrifuged autologous fat graft and percutaneous aponeurotomy for treating Dupuytren's disease Résultats préliminaires des aponévrotomies percutanées multiples et greffe de tissu adipeux autologue non centrifugé dans le traitement de la maladie de Dupuytren


Tuncel U., Kurt A., Gumus M., Aydogdu O., GÜZEL N., Demir O.

Hand Surgery and Rehabilitation, cilt.36, sa.5, ss.350-354, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 36 Sayı: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.hansur.2017.05.004
  • Dergi Adı: Hand Surgery and Rehabilitation
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.350-354
  • Anahtar Kelimeler: Aponeurotomy, Contracture, Dupuytren, Fat graft, Needle
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

The aim of this study was to describe our experience with treating Dupuytren's disease using needle aponeurotomy and non-centrifuged autologous fat grafting. The study included 17 patients (18 hands). Patients were treated with needle aponeurotomy and non-centrifuged autologous fat graft under general anesthesia. The fat grafts were injected into the surgical area so as to stay in contact with the operated site. An extension splint was used for 1 week postoperatively and the patients received hand therapy for 3 weeks. Before the treatment, the contracture in the proximal interphalangeal and metacarpophalangeal joints was a mean of 45.06 ± 13.44 degrees and 36.56 ± 13.09 degrees, respectively. It was 1.61 ± 1.65 and −0.56 ± 3.78 degrees at 3 months, respectively. The difference between these measurements was statistically significant. The mean follow-up period was 12 months. The results were satisfactory and no complications were observed during the follow-up period. Based on the results of the study, percutaneous aponeurotomy with non-centrifuged autologous fat grafting was found to have significantly beneficial effects in the treatment of Dupuytren's disease.